(Reuters) – The division of life sciences by Alphabet Inc. said yesterday that I was putting on hold one of its oldest and highest profile projects, a smart contact lens designed to help control sugar levels.
The project, begun in 2014, aims to help diabetics improve their levels of blood sugar by incorporating sensors in a contact lens to control glucose levels in their tears.
In a blog update, Verily cited here an insufficient consistency in the correlation between glucose concentrations and blood glucose concentrations to support the requirements of a medical device.
In fact, formerly part of the research and development unit of Google X of the technology company, he partnered with Novartis, Alcon's child care division, to develop the lens.
Alcon said in his own statement that the decision to pause the project was made in conjunction with Verily.
Businesses said they would continue to work on other two projects, "Smart Lens": one for presbyopia or longer vision and one for improving vision after cataract surgery.
He really received an investment of $ 800 million from the Singapore agent, Temasek last year.
Report by Munsif Vengattil in Bengaluru and Paresh Dave in San Francisco; Edition of Maju Samuel and Rosalba O'Brien